<DOC>
	<DOCNO>NCT00699426</DOCNO>
	<brief_summary>To test effect Nexium probiotic insulin secretion cardiovascular risk factor type 2 diabetic patient . Study Hypothesis : 1 . Nexium cause increase gastrin secretion increase insulin secretion thereby reduction HbA1c 2 . Probiotics change gut flora bloodpressure 3 . Probiotics cause change inflammation thrombosis .</brief_summary>
	<brief_title>The Effect Nexium Probiotics Insulin Secretion Cardiovascular Risk Factors Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>Type 2 diabetes ( WHO criteria ) treat metformin and/or sulfonylurea diet Males females 40 70 year HbA1c 6,010,0 Diabetes duration &gt; 1 year Kidney disease ( screatinine upper limit normal range ) . Liver disease ( ALAT increase &gt; 3 time upper limit normal range ALAT ) . Macroalbuminuria ( urinary albumin excretion &gt; 300 mg/day ) . Heart failure ( NYHA class lll lV ) Severe neuropathy ( symptoms + vibration perception threshold &gt; 50 measure biothesiometer . ) Neutropenia ( neutrophil count &lt; 2.0x10/l ) anemia ( hemoglobin &lt; 8mM men &lt; 7mM woman . Alcohol abuse Drug abuse Severe organic metabolic disease include cancer Cpeptide &lt; 0,3 pmol/l Medicine interaction Treatment insulin PPI medication ulcus disease Treatment warfarin coumarin derivation Pregnant breastfeed woman Allergy medication use study Participants may participate another clinical intervention trial</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>